| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RUNX2 |
| Uniprot No | Q13950 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 311-450aa |
| 氨基酸序列 | TSPSIHSTTPLSSTRGTGLPAITDVPRRISDDDTATSDFCLWPSTLSKKS QAGASELGPFSDPRQFPSISSLTESRFSNPRMHYPATFTYTPPVTSGMSL GMSATTHYHTYLPPPYPGSSQSQSGPFQTSSTPYLYYGTS |
| 预测分子量 | 41 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与RUNX2重组蛋白相关的文献示例(注：内容为模拟概括，实际文献请通过学术数据库核实)：
1. **文献名称**: "Recombinant RUNX2 Expression and Purification: Structural Insights into Osteogenic Regulation"
**作者**: Smith J, et al.
**摘要**: 报道了在大肠杆菌系统中高效表达可溶性RUNX2重组蛋白的优化方法，通过X射线晶体学解析其DNA结合域结构，揭示了其与骨特异性基因启动子结合的分子机制。
2. **文献名称**: "Functional Analysis of RUNX2 Phosphorylation Sites Using Recombinant Protein Mutants"
**作者**: Lee H, Kim T.
**摘要**: 通过构建不同磷酸化位点突变的RUNX2重组蛋白，证实了Ser-472位点的磷酸化对成骨细胞分化中靶基因激活的关键作用，为骨质疏松治疗提供新靶点。
3. **文献名称**: "RUNX2 Recombinant Protein Enhances Bone Regeneration in a Mouse Calvarial Defect Model"
**作者**: Zhang Y, et al.
**摘要**: 利用昆虫细胞表达系统制备高活性RUNX2重组蛋白，在小鼠颅骨缺损模型中验证其通过激活BMP信号通路显著促进骨组织再生能力。
4. **文献名称**: "Development of a RUNX2-Based Inducible System for Mesenchymal Stem Cell Differentiation"
**作者**: Müller R, et al.
**摘要**: 构建了携带重组RUNX2蛋白的可控表达载体，证明其在人间充质干细胞中诱导成骨分化的效率优于传统化学诱导剂，为骨组织工程提供新工具。
---
**提示**：建议通过PubMed或Web of Science搜索最新文献，关键词组合如"RUNX2 recombinant protein expression"或"RUNX2 purification function"。实际研究中需注意不同表达系统(如原核、真核)对蛋白活性的影响。
RUNX2 (Runt-related transcription factor 2) is a critical transcriptional regulator essential for skeletal development and osteoblast differentiation. As a member of the RUNX family, it contains a conserved Runt domain responsible for DNA binding and interaction with co-regulators like CBFβ. RUNX2 orchestrates the expression of osteogenic markers, including osteocalcin (BGLAP) and collagen type I alpha 1 (COL1A1), by binding to specific promoter sequences. It also integrates signaling pathways (e.g., BMP, Wnt, FGF) to balance osteogenesis with chondrogenesis during bone formation.
Recombinant RUNX2 protein is widely produced in expression systems (E. coli, mammalian cells) for functional studies. Bacterial systems yield non-phosphorylated protein, while eukaryotic systems preserve post-translational modifications crucial for activity. Purification typically employs affinity tags (His, GST) followed by cleavage and validation via SDS-PAGE/Western blot. Functional assays like EMSA and luciferase reporter systems confirm its DNA-binding and transcriptional activation capabilities.
In research, recombinant RUNX2 enables mechanistic studies of bone disorders (e.g., cleidocranial dysplasia caused by RUNX2 mutations) and pathological calcification. It serves as a tool to induce osteogenic differentiation in stem cells or assess inhibitors for conditions like osteoporosis. Additionally, its role in cancer metastasis (promoting EMT in breast/prostate cancers) has spurred interest in therapeutic targeting. However, challenges persist in maintaining protein stability and recapitulating native regulatory networks in vitro. Ongoing work focuses on optimizing delivery methods and interaction analyses to advance bone regeneration and anti-cancer strategies.
×
